{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T21:06:29Z","timestamp":1694639189823},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T00:00:00Z","timestamp":1276128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T00:00:00Z","timestamp":1276128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1038\/leu.2010.123","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T09:42:52Z","timestamp":1276162972000},"page":"1525-1528","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Clonal chromosomal abnormalities in CD34+\/CD38\u2212 hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors"],"prefix":"10.1038","volume":"24","author":[{"given":"T","family":"Bumm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A H","family":"Newell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H","family":"Lawce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Druker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Deininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,6,10]]},"reference":[{"key":"BFleu2010123_CR1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1080\/10428190410001723278","volume":"45","author":"M Loriaux","year":"2004","unstructured":"Loriaux M, Deininger M . Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 2004; 45: 2197\u20132203.","journal-title":"Leuk Lymphoma"},{"key":"BFleu2010123_CR2","doi-asserted-by":"publisher","first-page":"2811","DOI":"10.1182\/blood-2006-04-017400","volume":"108","author":"C Kovitz","year":"2006","unstructured":"Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J . Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 2006; 108: 2811\u20132813.","journal-title":"Blood"},{"key":"BFleu2010123_CR3","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1182\/blood-2007-01-070045","volume":"110","author":"E Jabbour","year":"2007","unstructured":"Jabbour E, Kantarjian HM, Abruzzo LV, O\u2019Brien S, Garcia-Manero G, Verstovsek S et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 2007; 110: 2991\u20132995.","journal-title":"Blood"},{"key":"BFleu2010123_CR4","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1002\/cncr.22936","volume":"110","author":"MW Deininger","year":"2007","unstructured":"Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 2007; 110: 1509\u20131519.","journal-title":"Cancer"},{"key":"BFleu2010123_CR5","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev.cellbio.17.1.387","volume":"17","author":"IL Weissman","year":"2001","unstructured":"Weissman IL, Anderson DJ, Gage F . Stem and progenitor cells: origins, phenotypes, lineage commitments, and transdifferentiations. Annu Rev Cell Dev Biol 2001; 17: 387\u2013403.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"BFleu2010123_CR6","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1182\/blood.V58.1.158.158","volume":"58","author":"PJ Fialkow","year":"1981","unstructured":"Fialkow PJ, Martin PJ, Najfeld V, Penfold GK, Jacobson RJ, Hansen JA . Evidence for a multistep pathogenesis of chronic myelogenous leukemia. Blood 1981; 58: 158\u2013163.","journal-title":"Blood"},{"key":"BFleu2010123_CR7","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","volume":"101","author":"T Bumm","year":"2003","unstructured":"Bumm T, Muller C, Al Ali HK, Krohn K, Shepherd P, Schmidt E et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 2003; 101: 1941\u20131949.","journal-title":"Blood"},{"key":"BFleu2010123_CR8","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1182\/blood.V79.4.997.bloodjournal794997","volume":"79","author":"D Claxton","year":"1992","unstructured":"Claxton D, Deisseroth A, Talpaz M, Reading C, Kantarjian H, Trujillo J et al. Polyclonal hematopoiesis in interferon-induced cytogenetic remissions of chronic myelogenous leukemia. Blood 1992; 79: 997\u20131002.","journal-title":"Blood"},{"key":"BFleu2010123_CR9","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","volume":"110","author":"A Theocharides","year":"2007","unstructured":"Theocharides A, Boissinot M, Girodon F, Garand R, Teo SS, Lippert E et al. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood 2007; 110: 375\u2013379.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2010123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010123","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2010123.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T13:33:59Z","timestamp":1648733639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2010123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,10]]},"references-count":9,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["BFleu2010123"],"URL":"https:\/\/doi.org\/10.1038\/leu.2010.123","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,10]]},"assertion":[{"value":"10 June 2010","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Oregon Health & Science University and BD have a financial interest in MolecularMD. The technology used in this research has been licensed to MolecularMD. This potential conflict of interest has been reviewed and managed by the Oregon Health & Science University Conflict of Interest in Research Committee and the Integrity Program Oversight Council. Oregon Health & Science University has clinical trial contracts with Novartis and Bristol-Myers Squibb to pay for patient costs, nurse and data manager salaries, and institutional overhead. BD does not derive salary nor does his laboratory receive funds from these contracts. MD is a consultant for Novartis and Bristol-Myers Squibb and was supported by Genzyme and Cytopia. The remaining authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}